Status:
UNKNOWN
The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Lymph Node Metastases
Gastric Cancer
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The aim of this study is intending to provide the optimal procedures of lymph node sorting for pathological examination after curative surgery for gastric cancer, which can discriminate the difference...
Eligibility Criteria
Inclusion
- 1\) Physical conditions compliance with the requirements for curative gastrectomy
- 2\) Consent to undergo the D2 lymphadenectomy
- 3\) Comply with the protocol during the whole study period
- 4\) No neoadjuvant therapy administration
- 5\) Sign informed consent and permission of withdraw in the whole study period
- 6\) Consent to provide the tissue specimens after surgery for this study
- 7\) Pathological examination confirmation the adenocarcinoma of stomach before surgery
- 8\) Estimation the overall survival after surgery no less than 6 months
- 9\) No anesthesia or operation contraindication disease
- 10\) cTanyNanyM0 stage demonstration by CT and endoscopic ultrasonography examinations
- 11\) Negative cytological detection in operation
- 12\) No seriously concomitance's diseases
- 13\) Karnofsky Performance Scores (KPS) more than 60
Exclusion
- 1\) Women during pregnant stage and breast-feed stage
- 2\) Women of childbearing age without any contraceptive measures
- 3\) Severe congestive heart failure, frequent arrhythmia, or myocardial infarction within 12 months
- 4\) Immunosuppressive therapists for organ transplantation
- 5\) Seriously uncontrolled recurrent infection
- 6\) other malignant tumors
- 7\) No abilities of self-knowledge or mental disorders
- 8\) Participating in other clinical trials
- 9\) Siewert I and II esophagogastric junction tumors
- 10\) Serious internal diseases obstruction surgery
Key Trial Info
Start Date :
April 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2020
Estimated Enrollment :
276 Patients enrolled
Trial Details
Trial ID
NCT03478449
Start Date
April 1 2018
End Date
December 30 2020
Last Update
November 13 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Hospital of Tianjin Medical University
Tianjin, China, 300060